title: Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.
abstract: Inhaled bronchodilator therapy is a mainstay of treatment for chronic obstructive pulmonary disease (COPD). Despite the number and types of treatments available, the control of symptoms and exacerbations remains suboptimal, and adherence to, and persistence with, inhaled therapy is generally poor. Results from clinical studies suggest that dual bronchodilator therapy with long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2 adrenergic receptor agonists (LABAs) may provide additional benefit over LAMA or LABA monotherapy without additive effects on safety and tolerability. Several combinations of a LAMA plus a LABA have recently become available in a single inhaler for maintenance therapy for adults with moderate-to-severe COPD, including aclidinium bromide/formoterol fumarate, glycopyrronium/indacaterol and umeclidinium/vilanterol. Here, we review clinical data demonstrating significant improvements in bronchodilation, 24-h symptoms, and health status with aclidinium/formoterol twice daily, and discuss how this treatment can be implemented in clinical practice as part of a patient-focused approach to disease control.
authors.affiliation: a 1 Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Tony
authors.initials: T
authors.lastname: D'Urzo
authors.affiliation: b 2 University of North Carolina, Chapel Hill, NC, USA.
authors.forename: James F
authors.initials: JF
authors.lastname: Donohue
authors.affiliation: c 3 University of Aberdeen, Aberdeen, UK.
authors.forename: David
authors.initials: D
authors.lastname: Price
authors.affiliation: d 4 Department of Pneumology, Vall d'Hebron University Hospital, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.
authors.forename: Marc
authors.initials: M
authors.lastname: Miravitlles
authors.affiliation: e 5 Clinical Research Institute, Medford, OR, USA.
authors.forename: Edward
authors.initials: E
authors.lastname: Kerwin
mesh_terms: D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D004417:Dyspnea / Q000188:drug therapy; D000068759:Formoterol Fumarate / Q000008:administration & dosage*; D006801:Humans; D008168:Lung / Q000187:drug effects*; D055118:Medication Adherence; D018727:Muscarinic Antagonists / Q000008:administration & dosage; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012129:Respiratory Function Tests; D014326:Tropanes / Q000008:administration & dosage*
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D001993:Bronchodilator Agents; D018727:Muscarinic Antagonists; D014326:Tropanes; C542859:aclidinium bromide; D000068759:Formoterol Fumarate
keywords: aclidinium bromide; bronchodilation; chronic obstructive pulmonary disease; combination therapy; dyspnea; formoterol fumarate; long-acting muscarinic antagonist; long-acting β2-agonist; symptoms